Home・Список акций・Novavax Inc

Novavax Inc

Закрыт

СекторЗдравоохранение

7.65 3.1

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.4

Макс.

7.6899999999999995

Ключевые показатели
By Trading Economics
Доход	-27M -9.5M
Продажи	-7.6M 140M
P/E Средняя по отрасли	3.112 64.641
Прибыль на акцию	-0.06
Рентабельность продаж	-6.803
Сотрудники	749
EBITDA	-29M -543K

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	+45.07% upside

Дивиденды
By Acuity
Следующий отчет о доходах	6 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-89M 1.2B
Предыдущая цена открытия	4.55
Предыдущая цена закрытия	7.65

Новостные настроения

By Acuity

50%

151 / 340 Рейтинг в Healthcare

Novavax Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 июл. 2026 г., 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 июл. 2026 г., 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 июл. 2026 г., 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 июл. 2026 г., 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 июл. 2026 г., 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 июл. 2026 г., 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 июл. 2026 г., 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 июл. 2026 г., 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 июл. 2026 г., 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 июл. 2026 г., 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Novavax Inc Прогноз

Целевая цена

By TipRanks

45.07% рост

Прогноз на 12 месяцев

Средняя 10.75 USD 45.07%

Максимум 19 USD

Минимум 7 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Novavax Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

4 ratings

Покупка

Удержание

Продажа

Основано на мнении 4 аналитиков, присваивавших рейтинги акциям Novavax Inc – Данные за последние 3 месяца.

Настроения

By Acuity

151 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.